Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
NCT ID: NCT02721537
Last Updated: 2022-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2016-09-30
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging
NCT03818802
The Effect of Synaquell™ in Contact Sport Athletes
NCT06104670
The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance
NCT01244360
Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood
NCT06384586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Healthy Collegiate Athletes
Healthy collegiate athletes will take active Nicotinamide Riboside
Nicotinamide Riboside
Three capsules, twice per day for 84 days
Arm B: Healthy Collegiate Athletes
Healthy collegiate athletes will take a matching placebo
Matching placebo
Three matching capsules, twice per day for 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide Riboside
Three capsules, twice per day for 84 days
Matching placebo
Three matching capsules, twice per day for 84 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (estimated based on height and weight) from 23 to 37
* Willing to provide informed consent, ingest test substance, and provide blood specimens
* Willing to comply with study instructions and maintain current level of physical activity throughout the study
Exclusion Criteria
* Contraindications to Magnetic Resonance Imaging (MRI), such as implanted medical devices, metal objects, or pacemakers
* History of epilepsy
* History of more than 3 concussions
* History of headache preceding a concussion
* History of depression preceding a concussion
* History of developmental delays or Attention Deficit Hyperactivity Disorder (ADHD)
* History of post-traumatic seizures
* History of complex spine and/or skull trauma
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Thorne HealthTech, Inc
INDUSTRY
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brent A. Bauer
M.D., Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brent A Bauer, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester, MN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota Center for Magnetic Resonance Research
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-006870
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.